3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neuroblastoma
3
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pheochromocytoma
1
Melanoma
1
Histiocytic Sarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
trametinib
5
dabrafenib
5
pembrolizumab
3
lenvatinib
3
cobimetinib
2
cemiplimab
2
atezolizumab
2
Vemurafenib
2
Radiotherapy, Intensity-Modulated
2
Paclitaxel
2
Nivolumab
2
zimberelimab
1
selpercatinib
1
fludarabine
1
cabozantinib
1
aldesleukin
1
Taxes
1
Ipilimumab
1
Immunoglobulin G
1
Disulfides
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Bevacizumab
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Carcinoma, Anaplastic
×
tipifarnib
×
1 year
×
Clear all
No trials found.